Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML

Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael J Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E. Nybakken, Keith Pratz, Judith Karp, B Douglas Smith, Mark J Levis

Research output: Contribution to journalArticle

Abstract

A hallmark of cancer is the disruption of differentiation within tumor cells. Internal tandem duplication mutations of the FLT3 kinase (FLT3/ITD) occur commonly in acute myeloid leukemia (AML) and are associated with poor survival, leading to efforts to develop FLT3 kinase inhibitors. However, FLT3 inhibitors have thus far met with limited success, inducing only a clearance of peripheral blasts with minimal BM responses. Quizartinib is a novel potent and selective FLT3 inhibitor currently being studied in clinical trials. In 13 of 14 FLT3/ITD AML patients with normal karyotype treated with quizartinib, we observed terminal myeloid differentiation of BM blasts in association with a clinical differentiation syndrome. The single patient whose blasts failed to differentiate had a preexisting C/EBPα mutation and another developed a C/EBPα mutation at disease progression, suggesting a mechanism of resistance to FLT3 inhibition. In vitro, in primary blasts cocultured with human BM stroma, FLT3 inhibition with quizartinib induced cell-cycle arrest and differentiation rather than apoptosis. The present study is the first description of terminal differentiation of cancer cells in patients treated with a tyrosine kinase inhibitor. These data highlight the importance of the differentiation block in the patho-genesis of AML.

Original languageEnglish (US)
Pages (from-to)4205-4214
Number of pages10
JournalBlood
Volume120
Issue number20
DOIs
StatePublished - Nov 15 2012

Fingerprint

Acute Myeloid Leukemia
Cells
Mutation
Cell Differentiation
Phosphotransferases
Neoplasms
Cell Cycle Checkpoints
Karyotype
Protein-Tyrosine Kinases
Disease Progression
Tumors
Clinical Trials
Apoptosis
Survival
quizartinib

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML. / Sexauer, Amy; Perl, Alexander; Yang, Xiaochuan; Borowitz, Michael J; Gocke, Christopher; Rajkhowa, Trivikram; Thiede, Christian; Frattini, Mark; Nybakken, Grant E.; Pratz, Keith; Karp, Judith; Smith, B Douglas; Levis, Mark J.

In: Blood, Vol. 120, No. 20, 15.11.2012, p. 4205-4214.

Research output: Contribution to journalArticle

Sexauer, A, Perl, A, Yang, X, Borowitz, MJ, Gocke, C, Rajkhowa, T, Thiede, C, Frattini, M, Nybakken, GE, Pratz, K, Karp, J, Smith, BD & Levis, MJ 2012, 'Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML', Blood, vol. 120, no. 20, pp. 4205-4214. https://doi.org/10.1182/blood-2012-01-402545
Sexauer, Amy ; Perl, Alexander ; Yang, Xiaochuan ; Borowitz, Michael J ; Gocke, Christopher ; Rajkhowa, Trivikram ; Thiede, Christian ; Frattini, Mark ; Nybakken, Grant E. ; Pratz, Keith ; Karp, Judith ; Smith, B Douglas ; Levis, Mark J. / Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML. In: Blood. 2012 ; Vol. 120, No. 20. pp. 4205-4214.
@article{4e49d19ea993426cbdedea4cd99547b7,
title = "Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML",
abstract = "A hallmark of cancer is the disruption of differentiation within tumor cells. Internal tandem duplication mutations of the FLT3 kinase (FLT3/ITD) occur commonly in acute myeloid leukemia (AML) and are associated with poor survival, leading to efforts to develop FLT3 kinase inhibitors. However, FLT3 inhibitors have thus far met with limited success, inducing only a clearance of peripheral blasts with minimal BM responses. Quizartinib is a novel potent and selective FLT3 inhibitor currently being studied in clinical trials. In 13 of 14 FLT3/ITD AML patients with normal karyotype treated with quizartinib, we observed terminal myeloid differentiation of BM blasts in association with a clinical differentiation syndrome. The single patient whose blasts failed to differentiate had a preexisting C/EBPα mutation and another developed a C/EBPα mutation at disease progression, suggesting a mechanism of resistance to FLT3 inhibition. In vitro, in primary blasts cocultured with human BM stroma, FLT3 inhibition with quizartinib induced cell-cycle arrest and differentiation rather than apoptosis. The present study is the first description of terminal differentiation of cancer cells in patients treated with a tyrosine kinase inhibitor. These data highlight the importance of the differentiation block in the patho-genesis of AML.",
author = "Amy Sexauer and Alexander Perl and Xiaochuan Yang and Borowitz, {Michael J} and Christopher Gocke and Trivikram Rajkhowa and Christian Thiede and Mark Frattini and Nybakken, {Grant E.} and Keith Pratz and Judith Karp and Smith, {B Douglas} and Levis, {Mark J}",
year = "2012",
month = "11",
day = "15",
doi = "10.1182/blood-2012-01-402545",
language = "English (US)",
volume = "120",
pages = "4205--4214",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML

AU - Sexauer, Amy

AU - Perl, Alexander

AU - Yang, Xiaochuan

AU - Borowitz, Michael J

AU - Gocke, Christopher

AU - Rajkhowa, Trivikram

AU - Thiede, Christian

AU - Frattini, Mark

AU - Nybakken, Grant E.

AU - Pratz, Keith

AU - Karp, Judith

AU - Smith, B Douglas

AU - Levis, Mark J

PY - 2012/11/15

Y1 - 2012/11/15

N2 - A hallmark of cancer is the disruption of differentiation within tumor cells. Internal tandem duplication mutations of the FLT3 kinase (FLT3/ITD) occur commonly in acute myeloid leukemia (AML) and are associated with poor survival, leading to efforts to develop FLT3 kinase inhibitors. However, FLT3 inhibitors have thus far met with limited success, inducing only a clearance of peripheral blasts with minimal BM responses. Quizartinib is a novel potent and selective FLT3 inhibitor currently being studied in clinical trials. In 13 of 14 FLT3/ITD AML patients with normal karyotype treated with quizartinib, we observed terminal myeloid differentiation of BM blasts in association with a clinical differentiation syndrome. The single patient whose blasts failed to differentiate had a preexisting C/EBPα mutation and another developed a C/EBPα mutation at disease progression, suggesting a mechanism of resistance to FLT3 inhibition. In vitro, in primary blasts cocultured with human BM stroma, FLT3 inhibition with quizartinib induced cell-cycle arrest and differentiation rather than apoptosis. The present study is the first description of terminal differentiation of cancer cells in patients treated with a tyrosine kinase inhibitor. These data highlight the importance of the differentiation block in the patho-genesis of AML.

AB - A hallmark of cancer is the disruption of differentiation within tumor cells. Internal tandem duplication mutations of the FLT3 kinase (FLT3/ITD) occur commonly in acute myeloid leukemia (AML) and are associated with poor survival, leading to efforts to develop FLT3 kinase inhibitors. However, FLT3 inhibitors have thus far met with limited success, inducing only a clearance of peripheral blasts with minimal BM responses. Quizartinib is a novel potent and selective FLT3 inhibitor currently being studied in clinical trials. In 13 of 14 FLT3/ITD AML patients with normal karyotype treated with quizartinib, we observed terminal myeloid differentiation of BM blasts in association with a clinical differentiation syndrome. The single patient whose blasts failed to differentiate had a preexisting C/EBPα mutation and another developed a C/EBPα mutation at disease progression, suggesting a mechanism of resistance to FLT3 inhibition. In vitro, in primary blasts cocultured with human BM stroma, FLT3 inhibition with quizartinib induced cell-cycle arrest and differentiation rather than apoptosis. The present study is the first description of terminal differentiation of cancer cells in patients treated with a tyrosine kinase inhibitor. These data highlight the importance of the differentiation block in the patho-genesis of AML.

UR - http://www.scopus.com/inward/record.url?scp=84869852580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869852580&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-01-402545

DO - 10.1182/blood-2012-01-402545

M3 - Article

C2 - 23012328

AN - SCOPUS:84869852580

VL - 120

SP - 4205

EP - 4214

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -